当前位置: X-MOL 学术Eur. J. Neurol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop)
European Journal of Neurology ( IF 5.1 ) Pub Date : 2024-03-28 , DOI: 10.1111/ene.16250
Irene Schiavetti 1 , Alessio Signori 1 , Angela Albanese 1 , Jessica Frau 2 , Eleonora Cocco 2, 3 , Lorena Lorefice 2 , Sonia di Lemme 4 , Roberta Fantozzi 4 , Diego Centonze 4, 5 , Doriana Landi 6 , Girolama Marfia 6 , Elisabetta Signoriello 7 , Giacomo Lus 7 , Chiara Zecca 8, 9 , Claudio Gobbi 8, 9 , Rosa Iodice 10 , Leonardo Malimpensa 11 , Cinzia Cordioli 12 , Diana Ferraro 13 , Francesca Ruscica 14 , Livia Pasquali 15 , Anna Repice 16 , Paolo Immovilli 17 , Maria Teresa Ferrò 18 , Simona Bonavita 19 , Massimiliano Di Filippo 20 , Gianmarco Abbadessa 21 , Flora Govone 22 , Maria Pia Sormani 1, 23 ,
Affiliation  

Cladribine tablets, a purine analogue antimetabolite, offer a unique treatment regimen, involving short courses at the start of the first and second year, with no further treatment needed in years 3 and 4. However, comprehensive evidence regarding patient outcomes beyond the initial 24 months of cladribine treatment is limited.

中文翻译:

克拉屈滨治疗 2 年后的治疗选择和疾病活动:意大利多中心研究 (CladStop)

克拉屈滨片剂是一种嘌呤类似物抗代谢药,提供独特的治疗方案,在第一年和第二年开始时进行短期疗程,第 3 年和第 4 年无需进一步治疗。然而,关于最初 24 个月后患者结局的综合证据克拉屈滨的治疗效果有限。
更新日期:2024-03-30
down
wechat
bug